• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Valneva Reports 3-Year Data For Chikungunya Vaccine IXCHIQ®

    GLOBENEWSWIRE

    Valneva Submits Chikungunya Vaccine IXCHIQ® to U.S. FDA

    GLOBENEWSWIRE

    Valneva & LimmaTech Begin Phase 2b Shigella Vaccine Study

    GLOBENEWSWIRE

    Valneva to Present at US & EU Conferences, Hold Investor Meetings

    GLOBENEWSWIRE

    Valneva Reports 9 Month 2024 Financial Results & Updates

    GLOBENEWSWIRE

    VALNEVA - Declaration of shares & voting rights: October 31, 2024

    GLOBENEWSWIRE

    Valneva To Present On Chikungunya At Leading Scientific Conferences

    GLOBENEWSWIRE

    Valneva And LimmaTech Awarded FDA Fast Track For Tetravalent Shigella

    GLOBENEWSWIRE

    Valneva Hosts Investor Day in New York City

    GLOBENEWSWIRE

    Valneva SE - Declaration Of Shares And Voting Rights - September

    GLOBENEWSWIRE

    Valneva Sets NYC Investor Day For October 10 At 10 AM ET

    GLOBENEWSWIRE

    Valneva Submits Label Extension for Chikungunya Vaccine

    GLOBENEWSWIRE

    Valneva Raises €60 Million In Private Placement

    GLOBENEWSWIRE

    Valneva Launches €60 Million Private Placement

    GLOBENEWSWIRE

    Valneva Declaration of shares and voting rights

    GLOBENEWSWIRE

    Valneva And Pfizer Report Positive Phase 2 Booster Results For Lyme Vaccine

    GLOBENEWSWIRE

    Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

    GLOBENEWSWIRE

    VALNEVA - Declaration of shares and voting rights: July 31, 2024

    GLOBENEWSWIRE

    Valneva Pays LimmaTech $10M For Shigella Vaccine

    FIERCE BIOTECH

    Valneva And LimmaTech Partner On Shigella Vaccine Development

    GLOBENEWSWIRE

    CEPI Grants Valneva $41.3M To Expand Access To Chikungunya Vaccine

    GLOBENEWSWIRE

    Valneva`s Ixchiq (Chikungunya vaccine) Receives Approval In Europe

    EMA

    Valneva And Pfizer Complete Primary Vaccination In Lyme Trial

    GLOBENEWSWIRE

    Declaration of shares and voting rights - Valneva SE - June 30, 2024

    GLOBENEWSWIRE

    Valneva Receives Marketing Authorization In Europe For First Chikungunya IXCHIQ

    GLOBENEWSWIRE

    Valneva Announces Outcome of General Meeting Appointment of a New Director

    GLOBENEWSWIRE

    Valneva announces Health Canada approval for world’s first Chikungunya vaccine

    GLOBENEWSWIRE

    Harmony Bio: Positive Pitolisant Data In Myotonic Dystrophy Type 1

    GLOBENEWSWIRE

    VALNEVA - Declaration of shares and voting rights: May 31, 2024

    GLOBENEWSWIRE

    Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

    GLOBENEWSWIRE

    Valneva`s Lyme Disease Phase 2 Trials Published In Lancet ID

    GLOBENEWSWIRE

    EU regulator recommends use of Valneva`s chikungunya vaccine

    REUTERS

    Valneva Receives EMA`s Positive CHMP Opinion for its Chikungunya Vaccine

    GLOBENEWSWIRE

    Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

    GLOBENEWSWIRE

    Valneva Positive Adolescent Phase 3 Chikungunya Vaccine Data

    GLOBENEWSWIRE

    Valneva Q1 2024 Results And Corporate Updates

    GLOBENEWSWIRE

    Valneva: Shares And Voting Rights Declaration As Of April 30

    GLOBENEWSWIRE

    Valneva rallies behind launch of its new chikungunya vaccine

    FIERCE PHARMA

    Declaration of voting rights - Valneva SE, March 2024

    GLOBENEWSWIRE

    Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

    GLOBENEWSWIRE

    Valneva Announces Filing of 2023 Universal Registration Document & US Form 20-F

    GLOBENEWSWIRE

    Valneva to Present on its Chikungunya Vaccine IXCHIQ in Multiple Events

    GLOBENEWSWIRE

    Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

    GLOBENEWSWIRE

    French biotech company Valneva raises product sales guidance

    REUTERS

    Valneva Announces Extension of the Interest-Only Period of Its Debt Facility

    GLOBENEWSWIRE

    VALNEVA Declaration of shares and voting rights - February 29, 2024

    GLOBENEWSWIRE

    Valneva to Present at Upcoming TD Cowen Healthcare Investor Conferences

    GLOBENEWSWIRE

    ACIP recommends expanded use for Valneva`s chikungunya vaccine & Covid boosters

    ENDPTS

    ACIP Recommends Use of Valneva™s Single-Dose Chikungunya Vaccine IXCHIQ

    GLOBENEWSWIRE

    Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

    GLOBENEWSWIRE

    VALNEVA: Declaration of shares and voting rights - January 31, 2024

    GLOBENEWSWIRE

    Valneva sells priority review voucher for $103M, R&D to benefit

    FIERCE BIOTECH

    Valneva Vaccinates First Participant in Trial of Chikungunya Vaccine

    GLOBENEWSWIRE

    VALNEVA - Declaration of shares and voting rights: December 31, 2023

    GLOBENEWSWIRE

    Valneva to Conduct Investor Meetings during J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Valneva Provides Updated 2023 Financial Guidance

    GLOBENEWSWIRE

    Valneva Shareholders Approve EGM Resolutions

    GLOBENEWSWIRE

    VALNEVA Declaration of shares and voting rights - November 30, 2023

    GLOBENEWSWIRE

    Valneva Reports Positive 24-Month Antibody Persistence Data for IXCHIQ®

    GLOBENEWSWIRE

    Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for VLA15

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.